Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison

被引：0
|
作者：
Nash, Peter [1 ]
McInnes, Iain B. [2 ]
Mease, Philip J. [3 ,4 ]
Choy, Ernest H. [5 ,6 ]
Thom, Howard [7 ]
Kalyvas, Chrysostomos [8 ]
Gandhi, Kunal [9 ]
Mpofu, Shephard [10 ]
Jugl, Steffen [10 ]
机构：
[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Cardiff Univ, Sch Med, Rheumatol Sect, Cardiff, S Glam, Wales
[6] Cardiff Univ, CREATE Ctr, Div Infect & Immun, Cardiff, S Glam, Wales
[7] Univ Bristol, Bristol, Avon, England
[8] MAPI Grp, Houten, Netherlands
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1738
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF BIMEKIZUMAB AND SECUKINUMAB AT 52 WEEKS FOR THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
    Maksymowych, W. P.
    Thom, H.
    Morup, M.
    Taieb, V
    Willems, D.
    Gaffney, K.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S30
  • [42] A COST PER RESPONDER ANALYSIS OF SECUKINUMAB VS. ADALIMUMAB BASED ON A MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY DATA FOR THE TREATMETN OF PSORIATIC ARTHRITIS AT 48 WEEKS FROM THE IRISH PAYER PERSPECTIVE
    Gunda, P.
    Nikoglou, E.
    Jugl, S. M.
    Murphy, A.
    VALUE IN HEALTH, 2017, 20 (09) : A532 - A532
  • [43] Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis
    Cohan, Stanley
    Tencer, Tom
    Arndorfer, Stella
    Zhu, Xuelian
    Zivkovic, Marko
    Kumar, Jinender
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [44] Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
    Garcia-Foncillas, J.
    Bokemeyer, C.
    Italiano, A.
    Keating, K.
    Paracha, N.
    Fellous, M.
    Marian, M.
    Fillbrunn, M.
    Gao, W.
    Ayyagari, R.
    Lassen, U. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S401 - S401
  • [45] Comparative Effectiveness Without Head-to-Head Trials A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept
    Signorovitch, James E.
    Wu, Eric Q.
    Yu, Andrew P.
    Gerrits, Charles M.
    Kantor, Evan
    Bao, Yanjun
    Gupta, Shiraz R.
    Mulani, Parvez M.
    PHARMACOECONOMICS, 2010, 28 (10) : 935 - 945
  • [46] COMPARATIVE EFFECTIVENESS IN PAIN AND HAQ-DI IMPROVEMENT FOR BARICITINIB VERSUS ADALIMUMAB, TOCILIZUMAB, AND TOFACITINIB MONOTHERAPIES IN CSDMARD-NAIVE RHEUMATOID ARTHRITIS PATIENTS: A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
    Fautrel, R.
    Zhu, B.
    Taylor, P. C.
    van de Laar, M.
    Emery, P.
    De Leonardis, F.
    Gaich, C.
    Nicolay, C.
    Kadziola, Z.
    De La Torre, I.
    Fleischmann, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 973 - 974
  • [47] Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naive Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
    Fautrel, Bruno
    Zhu, Baojin
    Taylor, Peter C.
    van de Laar, Mart
    Emery, Paul
    de Leonardis, Francesco
    Gaich, Carol L.
    Nicolay, Claudia
    Kadziola, Zbigniew
    de la Torre, Inmaculada
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] A COST PER RESPONDER ANALYSIS OF SECUKINUMAB VS ADALIMUMAB BASED ON A MATCHING-ADJUSTED INDIRECT COMPARISON FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM A GERMAN PAYER PERSPECTIVE
    Gunda, P.
    Kandhare, A.
    Nikoglou, E.
    Jugl, S. M.
    Kneidl, J.
    Neidhardt, K.
    VALUE IN HEALTH, 2016, 19 (07) : A537 - A537
  • [49] Comparative Effectiveness Without Head-to-Head TrialsA Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept
    James E. Signorovitch
    Eric Q. Wu
    Andrew P. Yu
    Charles M. Gerrits
    Evan Kantor
    Yanjun Bao
    Shiraz R. Gupta
    Parvez M. Mulani
    PharmacoEconomics, 2010, 28 : 935 - 945
  • [50] Matching-adjusted indirect comparisons of ixekizumab and secukinumab using etanercept and ustekinumab bridge comparators
    Wu, J. J.
    Saure, D.
    Schacht, A.
    Mallbris, L.
    Wilhelm, S.
    Dossenbach, M.
    Burkhardt, N.
    Nast, A.
    Warren, R. B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 44 - 44
12345